Recruiting

Mitochondrial Function

Sponsor:

University of Iowa

Code:

NCT07244809

Conditions

Adverse Childhood Experience

Endothelial Function (FMD)

Endothelial Injury

Mitochondrial Function

Oxidative Stress

Eligibility Criteria

Sex: All

Age: 18 - 29

Healthy Volunteers: Accepted

Interventions

Mitoquinone mesylate (MitoQ)

Placebo

Study Details

Brief summary:

Adverse childhood experiences (ACEs) represent highly stressful events in the first 18 years of life that include abuse, neglect, and household and community-level dysfunction. Greater exposure to ACEs are associated with greater increases in the risk of cardiovascular diseases and death. Our laboratory has previously observed that vascular function is disrupted in young adults with prior ACE exposure, even though these individuals appear to be healthy clinically (i.e., no classic clinical cardiovascular disease risk factors). There is a need to identify and understand the biological mechanisms underlying these vascular impairments to inform effective interventions to reduce cardiovascular risks the millions of individuals affected by ACEs.

The body's response to stress is coordinated across various systems, all of which depend on energy supplied by mitochondria (often referred to as the "powerhouse of cells"). Based on new evidence across multiple physiological systems from our team, our overarching hypothesis is that disruption of mitochondrial function contributes to cardiovascular impairments among young adults with ACEs. Here we propose the initial pilot work necessary to begin to understand these associations, which will directly inform identification of individuals who may be most vulnerable to stress-related cardiovascular risk and the development of interventions to promote cardiovascular-stress resilience.

Our aims are to:

1. Determine whether mitochondrial oxidative stress contributes to impaired vascular function among young adults who experienced early life adversity.
2. Determine whether reducing mitochondrial oxidative stress improves the cellular stress and integrated cardiovascular response to laboratory-based psychosocial stress among young adults who experienced early life adversity.

Conditions

Adverse Childhood Experience

Endothelial Function (FMD)

Endothelial Injury

Mitochondrial Function

Oxidative Stress

Study ID

NCT07244809

Start date

Oct 13, 2025

Status verified date

Nov, 2025

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Jul 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 29

Healthy Volunteers: Accepted

Inclusion Criteria:

  • 18-29 years
  • ACE score >=4

Exclusion Criteria:

  • Resting arterial blood pressure >140/90 mmHg
  • BMI <=17 or >= 35
  • Are on a weight-loss diet or involved in a formal weight-loss program or are not intentionally weight stable for 6 months (+/- 5 kg) prior to the study.
  • Cardiovascular or metabolic prescription drug use
  • Vasoactive antidepressant drug use (SSRIs and clonidine)
  • Current heavy alcohol use, as defined as binge drinking on 5 or more days in the last month, or consuming more than 7 (women) or 14 (men) drinks per week in the last month (per NIAAA definition)
  • Current or recent (within the last 6 mo.) illicit drug use disorder as indicated by a score of 3 or greater on the Drug Abuse Screening Test (DAST-10)
  • Current tobacco or nicotine use
  • Vaping
  • Regular vigorous (>6 METs) aerobic exercise (>4 bouts/week, >30 min/bout)
  • dietary supplementation with antioxidants or habitual use of NSAIDs
  • Currently pregnant or breastfeeding

Study Design

Enrollment

300 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Mitoquinone Mesylate (MitoQ)

Mitoquinone Mesylate (160 mg, single dose)

placebo comparator: Placebo

Matched placebo (microcrystalline cellulose and tapioca, 160 mg, single dose)

Interventions

Mitoquinone mesylate (MitoQ)

Participants will consume a single 160 mg dose of mitoquinone mesylate, provided in the form of 6, 20 mg capsules, with water.

Placebo

Participants will consume a single 160 mg dose of microcrystalline cellulose and tapioca (placebo), provided in 20 mg capsules, with water.

Primary outcome measure

  • Vascular endothelial function [ Time Frame: Prior to supplementation and 60 minutes after supplementation ]
  • Blood pressure [ Time Frame: 75 minutes after supplementation, during, and for 45 minutes after completion of the Trier Social Stress Test. ]
  • Endothelial Cell Microparticle Release [ Time Frame: 60 minutes after supplementation and immediately following, 5-10 min, 15-20 min, and 45 min following the Trier Social Stress Test. ]
  • Cortisol [ Time Frame: 60 minutes after supplementation and immediately following, 5-10 min, 15-20 min, and 45 min following the Trier Social Stress Test. ]

Central Contacts and Locations

Central contacts

Locations

Integrative Laboratory of Applied Physiology and Lifestyle Medicine

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

More Information

Sponsor

University of Iowa

Last update posted

Nov 24, 2025

Last verified

Nov, 2025

Keywords

  • flow mediated dilation
  • mitoquinone mesylate
  • placebo
  • early life adversity
  • trier social stress test

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Iowa on 2025-11-24.